World's First Clinical Case of Gene-Activated Bone Substitute Application

Treatment of patients with large bone defects is a complex clinical problem. We have initiated the first clinical study of a gene-activated bone substitute composed of the collagen-hydroxyapatite scaffold and plasmid DNA encoding vascular endothelial growth factor. The first patient with two nonunio...

Descripción completa

Detalles Bibliográficos
Autores principales: Bozo, I. Y., Deev, R. V., Drobyshev, A. Y., Isaev, A. A., Eremin, I. I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116519/
https://www.ncbi.nlm.nih.gov/pubmed/27891264
http://dx.doi.org/10.1155/2016/8648949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116519/
https://www.ncbi.nlm.nih.gov/pubmed/27891264
http://dx.doi.org/10.1155/2016/8648949

Ejemplares similares